NRXS (Neuraxis) Valuation Rank


NRXS Neuraxis Inc NRXS
42 GF Score
Price $7.21
GF Value $2.92
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Neuraxis Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Neuraxis Valuation Rank Related Terms

NRXS
42GF Score
Neuraxis Inc NRXS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuraxis (NRXS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuraxis stock appears to be overvalued. The current stock price of $7.21 is trading 146.9% above its estimated GF Value™ of $2.92. GuruFocus considers Neuraxis to be Significantly Overvalued.

Key valuation signals for NRXS:

  • Valuation Rank:
  • GF Value™: $2.92 vs. price of $7.21 (146.9% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NRXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuraxis Business Description

Address 11611 North Meridian Street, Suite 330, Carmel, IN, USA, 46032
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
42GF Score

Get the complete analysis for NRXS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.21
Price
$2.92
GF Value